ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,118Medicare Part D Prescriptions Filled, Including Refills

Rank: 53 out of 434

$487K Total Retail Price of All Prescriptions

Rank: 43 out of 434

790 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
13% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nevada
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 790 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

11% of this provider’s 790 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 8,129 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

15% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$53 was the average price of a prescription from this provider, compared to $52 among peers.

Prescriptions per Patient

12 is the average number of prescriptions (including refills) per patient, compared to an average of 13.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nevada
LISINOPRIL 577 517 1 1
SIMVASTATIN 475 432 2 2
HYDROCODONE-ACETAMINOPHEN 376 282 S3 3 4
ATORVASTATIN CALCIUM 344 307 4 19
ATENOLOL 324 302 5 16
OMEPRAZOLE 321 281 6 5
LEVOTHYROXINE SODIUM 318 300 7 3
LOVASTATIN 306 300 8 10
AMLODIPINE BESYLATE 299 270 9 6
METFORMIN HCL 271 220 10 7
ZOLPIDEM TARTRATE 226 199 11 11
ALENDRONATE SODIUM 224 213 12 15
METOPROLOL TARTRATE 188 173 13 12
LISINOPRIL-HYDROCHLOROTHIAZIDE 172 166 14 21
FUROSEMIDE 116 104 15 9
LOSARTAN POTASSIUM 115 106 16 13
POTASSIUM CHLORIDE 101 93 17 20
WARFARIN SODIUM 97 94 18 18
FLUTICASONE PROPIONATE 94 89 19 26
PRAVASTATIN SODIUM 92 88 20 17
TAMSULOSIN HCL 91 83 21 29
FLUOXETINE HCL 86 80 22 32
GEMFIBROZIL 83 63 23 62
ATENOLOL-CHLORTHALIDONE 80 76 24 157
CLOPIDOGREL 78 68 25 41
GLYBURIDE 77 64 R 26 51
ALLOPURINOL 75 66 27 25
BENAZEPRIL HCL 74 70 28 49
METOPROLOL SUCCINATE 72 57 29 22
HYDROCHLOROTHIAZIDE 70 70 30 8
PROAIR HFA 70 64 30 60
CARVEDILOL 70 54 30 24
DONEPEZIL HCL 68 68 33 35
DIGOXIN 67 61 34 69
RANITIDINE HCL 65 65 35 31
OXYCODONE-ACETAMINOPHEN 63 52 S2 36 74
GABAPENTIN 62 41 37 14
TRIAMTERENE-HCTZ 59 51 38 47
LOSARTAN-HYDROCHLOROTHIAZIDE 58 58 39 39
NAPROXEN 57 53 40 75
FINASTERIDE 57 49 40 54
LIPITOR 56 47 42 133
CIPROFLOXACIN HCL 56 54 42 55
DILTIAZEM 24HR CD 55 41 44 126
TERAZOSIN HCL 54 54 45 40
DOXAZOSIN MESYLATE 53 51 46 111
ADVAIR DISKUS 53 49 46 52
CITALOPRAM HBR 51 47 48 23
PAROXETINE HCL 50 50 49 61
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 9, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.